291.12M
Market cap
Current P/E
7.35x
Forward P/E

About

Health care
Sector
Biotechnology
Industry

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer.

Similar securities

Based on sector and market capitalization

Report issue